Regenerative MedicineResearch PaperPaywall

Citrus flavanone hesperidin calms inflammation and scarring in dystrophic mouse muscle

In mdx mice with Duchenne-type dystrophy, oral hesperidin improved grip strength and shifted muscle immune, metabolic and fibrotic signatures toward healthy.

Friday, November 20, 2026 1 view
Published in Food Funct
Sliced oranges and grapefruit on a wooden board beside a lab bench with a mouse muscle tissue slide under a microscope

Summary

Hesperidin is a flavanone found in citrus fruit. Researchers tested it in mdx mice, a standard model of Duchenne muscular dystrophy, where muscle lacks dystrophin and becomes inflamed, scarred and energy-poor. Five-week-old mice received 10 or 20 mg/kg orally for 4 weeks. Treated mice had better grip strength, less immobility, less muscle fragility, more organized fibers, and less inflammation and collagen. Gene-expression, metabolite and single-cell analyses suggested hesperidin restored mitochondrial energy-production genes, lowered inflammatory chemokines and fibrosis markers, and shifted macrophages from a pro-inflammatory to a repair-type state. It also dampened TGF-β/Smad and NF-κB signaling. These are mouse and cell data from an abstract only, with no human testing and no lifespan outcome. The mechanisms (inflammation, fibrosis, mitochondrial function) overlap with muscle aging, but the human relevance remains unproven.

Detailed Summary

Muscle loss, chronic inflammation, fibrosis and mitochondrial decline are shared themes between muscular dystrophy and aging muscle. Duchenne muscular dystrophy (DMD) is a severe genetic disease, but the secondary damage that follows dystrophin loss, including immune activation, scarring and energy failure, is a useful model for studying how to protect muscle tissue.

This study tested hesperidin, a citrus flavanone, in mdx mice, the standard DMD model. Five-week-old mice received 10 or 20 mg/kg orally for 4 weeks. The team combined network pharmacology, bulk RNA sequencing, untargeted metabolomics, single-cell RNA sequencing, Western blots, immunofluorescence and a macrophage cell experiment.

On function, treated mice showed improved grip strength, reduced immobility and less muscle fragility. On tissue, muscle showed better fiber organization with less inflammation and collagen. Mechanistically, hesperidin reversed the loss of oxidative phosphorylation genes (including NDUFA/B/C and COX6A1) and suppressed the chemokines CCL2 and CCL7 and fibrotic markers COL1A1 and POSTN. Metabolomics showed shifts in creatine, arginine, glutathione and acylcarnitine pathways toward wild-type. Single-cell data showed fewer inflammatory macrophages, less fibrotic differentiation and rebalanced B and T cells. Protein work indicated reduced TGF-β/Smad2/3 and NF-κB signaling and restored GPX4/SLC7A11, a ferroptosis-related axis. A virtual Tgfb1 knockout suggested TGF-β1 is only partly responsible. In LPS-stimulated macrophages, hesperidin suppressed iNOS and CD86 about as effectively as dexamethasone.

The implication is that a food-derived compound moved mechanism, tissue structure and some measures of function together in this model, pointing to inflammation-fibrosis crosstalk as a tractable target. That is relevant to age-related muscle decline, though this was not tested.

Caveats: this is a mouse and cell study, summarized from the abstract alone. The treatment lasted 4 weeks, group sizes were not reported, and no lifespan, dystrophin restoration or human data were given. Many findings are transcriptional or computational, and the dexamethasone comparison was in cells only.

Key Findings

  • Oral hesperidin (10 or 20 mg/kg, 4 weeks) improved grip strength and reduced immobility and muscle fragility in mdx mice.
  • Mechanism: restored oxidative phosphorylation genes and metabolites while suppressing CCL2, CCL7, COL1A1 and POSTN.
  • Single-cell analysis showed macrophages shifting from pro- to anti-inflammatory states, with reduced TGF-β/Smad2/3 and NF-κB signaling.
  • In LPS-stimulated macrophages, hesperidin suppressed iNOS and CD86 as effectively as dexamethasone.
  • No lifespan, human or dystrophin-restoration data were reported; TGF-β1 involvement was only partial.

Methodology

Five-week-old mdx mice received oral hesperidin at 10 or 20 mg/kg for 4 weeks versus untreated mdx and wild-type controls. Outcomes combined behavior and strength tests, histology, network pharmacology, bulk and single-cell RNA-seq, untargeted metabolomics, Western blot and immunofluorescence, plus an in vitro macrophage assay and virtual Tgfb1 knockout.

Study Limitations

The summary is based on the abstract only, so sample sizes, statistics and effect sizes are unavailable. The work is in a single mouse model over 4 weeks with no lifespan or human data, and much of the evidence is transcriptional or computational. Cell comparison to dexamethasone does not establish equivalence in vivo.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: